Reddy's, Zydus, and Ranbaxy hit by new regulatory actions
This article was originally published in Scrip
Executive Summary
A raft of unfavourable regulatory news has hit several major Indian firms, with the US FDA issuing an import alert for products from Dr Reddy's Mexican facility and a warning letter against Zydus Cadila for current good manufacturing practice deviations at its facility in Sarkhej in India.